Quick Answer
Aligos Therapeutics, Inc. reported Shares Outstanding of 6.18 million shares for fiscal year 2025.
Aligos Therapeutics, Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 6.18M | +59.9% |
| 2024 | 3.86M | -95.2% |
| 2024 | 79.90M | +2559.9% |
| 2023 | 3.00M | -93.0% |
| 2022 | 42.92M | +0.5% |
| 2021 | 42.69M | +12.0% |
| 2020 | 38.12M | +870.5% |
| 2019 | 3.93M | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | 6.15M | +85.1% | +0.0% |
| June 30, 2025 | 6.15M | -92.3% | +0.6% |
| March 31, 2025 | 6.11M | -91.9% | +58.2% |
| December 31, 2024 | 3.86M | +28.6% | +16.2% |
| September 30, 2024 | 3.32M | -92.4% | -95.8% |
| August 31, 2024 | 79.90M | — | +0.1% |
| June 30, 2024 | 79.79M | +83.4% | +5.4% |
| March 31, 2024 | 75.67M | +76.2% | +2419.0% |
- Aligos Therapeutics, Inc. showed an increase of +59.9% in Shares Outstanding compared to the prior fiscal year.
- Over the 2019–2025 period, Aligos Therapeutics, Inc.’s shares outstanding has grown by 57.3% (from 3.93 million shares to 6.18 million shares).
- The most recent figure is from Aligos Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: